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Introduction
============

Human telomerase reverse transcriptase (TERT) is well known as the catalytic subunit of telomerase, and it elongates telomere using telomerase RNA component (TERC), the specific RNA template[@B0]. Although TERT polymerizes telomeric DNA as a component of telomerase, the structural and phylogenetic analyses indicate that TERT is closely related with viral RNA-dependent RNA polymerases (RdRPs) as well as viral reverse transcriptase, and shares domains with these polymerases[@B1][@B2][@B3]. RdRP is the enzyme that generates complementary RNA strand to a template RNA. The enzyme is encoded not only in viruses but also in model organisms, such as plant, yeast and worm, and double-stranded RNA synthesis by RdRP contributes to transcriptional and post-transcriptional gene silencing in these organisms[@B4][@B5]. Although human RdRP had been missing for a long time, we found RdRP activity in human TERT in 2009[@B6].

We first confirmed RdRP activity of TERT with recombinant protein[@B6], then established a sensitive *in vitro* assay to detect RdRP activity of endogenous TERT[@B7]. Here, we demonstrate the *in vitro*RdRP assay (IP-RdRP assay) for endogenous TERT. This method starts with immunoprecipitation (IP) of endogenous TERT, and is followed by *in vitro* RdRP reaction, in which radioactive ribonucleotides are incorporated into nascent RNA strands.

Protocol
========

1. Reagent Setup
----------------

1.  **Reagents used for Cell Synchronization** To generate Dulbecco\'s modified Eagle\'s medium (DMEM) containing 2.5 mM thymidine, dissolve 30.28 mg of thymidine per 1 mL of tissue culture grade water to prepare 125 mM thymidine. Filtrate the solution with a 0.22 μm syringe filter unit. Add 1 mL of freshly prepared 125 mM thymidine per 50 mL of DMEM supplemented with 10% (vol/vol) fetal bovine serum (FBS).To generate DMEM containing 0.1 μg/mL of nocodazole, dissolve nocodazole in dimethyl sulfoxide (DMSO) to prepare 5 μg/μL nocodazole. Add 1 µL of 5 µg/ µL nocodazole per 50 mL of DMEM supplemented with 10% (vol/vol) FBS.To generate DMEM containing 0.002% (vol/vol) of DMSO, add 1 µL of DMSO per 50 mL of DMEM supplemented with 10% (vol/vol) FBS.

2.  **Reagents used for IP-RdRP assay** Prepare lysis buffer A: 150 mM NaCl, 20 mM Tris-HCl (pH 7.4) and 0.5% (vol/vol) Nonidet P-40 (NP-40). Store the reagent at 4 °C.Prepare 5x acetate buffer: 50 mM 2-\[4-(2-Hydroxyethyl)-1-piperazinyl\]ethanesulfonic acid (HEPES)-KOH (pH 7.8), 500 mM potassium acetate and 20 mM MgCl~2~. Store the reagent at room temperature.Prepare Wash buffer 1: 1x acetate buffer, 10% (vol/vol) glycerol, 0.1% (vol/vol) Triton X-100 and 0.06x protease inhibitor cocktail, ethylenediamenetetraacetic acid (EDTA)-free. Prepare Wash buffer 1 on the day of use or the day before use. Store the reagent at 4 °C.Prepare AGC solution: 1x acetate buffer, 10% (vol/vol) glycerol and 0.02% (wt/vol) 3-\[(3-Cholamidopropyl)dimethylammonio\]-1-propanesulfonat (CHAPS). Store the reagent at 4 °C.To generate AGC solution containing 2 mM CaCl~2~, add 100 µL of 1 M CaCl~2~ per 50 mL of AGC solution. Store the reagent at 4 °C.To generate AGC solution containing 3 mM ethylene glycol bis (b-aminoethylether)-N,N,N\',N\'-tetraacetic acid (EGTA), add 375 µL of 0.4 M EGTA (pH 7.5) per 50 mL of AGC solution. Store the reagent at 4 °C.Prepare Wash buffer 2: 1x acetate buffer and 0.02% (wt/vol) CHAPS. Store the reagent at 4 °C.Prepare HMD solution: 0.2 M HEPES-KOH (pH 7.8), 40 mM MgCl~2~ and 2 mM dithiothreitol (DTT). Store the reagent at -20 °C. NOTE: HMD solution should be renewed at least in three months.Prepare 2x Proteinase K buffer: 20 mM Tris-HCl (pH 7.6), 20 mM EDTA and 1% (wt/vol) sodium dodecyl sulfate (SDS). Store the reagent at -20 °C.Prepare 2x loading buffer: 95% (vol/vol) formamide, 20 mM EDTA and 1% (wt/vol) Orange G. Store the reagent at -20 °C.

2. Preparation of HeLa cells
----------------------------

NOTE: Prepare HeLa cells synchronized in mitotic phase (manipulated) or dividing asynchronously (unmanipulated). Culture the cells in the presence of 5% CO~2~ at 37 °C.

1.  **Synchronization of HeLa cells in mitosis** Plate 1 x 10^6^ of HeLa cells with 10 mL of DMEM supplemented with 10% (vol/vol) FBS in a 10 cm culture dish.Two days after plating, replace the medium with 10 mL of DMEM containing 2.5 mM thymidine and 10% (vol/vol) FBS. Culture the cells for 24 h.Wash the cells three times with 10 mL of phosphate buffered saline (PBS) (-), and culture the cells with 10 mL of DMEM containing 10% (vol/vol) FBS for 6 h.Replace the medium with 10 mL of DMEM containing 0.1 µg/mL of nocodazole and 10% (vol/vol) FBS, and culture the cells for 14 h.Shake the culture dish gently, and retrieve the supernatant containing the detached mitotic cells. Count the cell number for the IP-RdRP assay.Centrifuge the sample at 490 x *g* for 5 min at 4 °C, and discard the supernatant. NOTE: The cell pellet can be stored at -80 °C.

2.  **Preparation of unmanipulated HeLa cells** Plate 1 x 10^6^ of HeLa cells with 10 mL of DMEM supplemented with 10% (vol/vol) FBS in a 10 cm culture dish.Two days after plating, replace the medium with 10 mL of DMEM containing 10% (vol/vol) FBS. Culture the cells for 30 h.Replace the medium with 10 mL of DMEM containing 0.002% (vol/vol) DMSO and 10% (vol/vol) FBS, and culture the cells for 14 h.Collect the cells by trypsinization using 0.7 mL of trypsin (2.5 g/L) containing 1 mM EDTA. Count the cell number for the IP-RdRP assay.Centrifuge the sample at 490 x *g* for 5 min at 4 °C, and discard the supernatant. NOTE: The cell pellet can be stored at -80 °C.

3. IP-RdRP Assay
----------------

1.  **Protein A-agarose bead preparation** Transfer 1 mL (bed volume 500 µL) of affinity resin to a 1.5 mL microcentrifuge tube. Centrifuge at 800 x *g* for 5 min at 4 °C, and discard the supernatant.Add 800 µL of Lysis buffer A to the beads, and mix well by inverting the tube several times. Centrifuge at 800 x *g* for 3 min at 4 °C, and discard the supernatant. Repeat this step twice (total three washes).Add 800 µL of Lysis buffer A to the beads, mix well by inverting the tube several times. Rotate the tube overnight (or for at least 4 h) at 4 °C on a rotary shaker.Centrifuge the tube at 800 x *g* for 3 min at 4 °C, and discard the supernatant.Add 500 µL of Lysis buffer A to the beads, and mix well by inverting the tube several times. Store the beads at 4 °C.

2.  **Preparation of cell lysate** (Optional) If the cells are frozen in step 2, place and thaw the frozen cells on ice until the cells become loose.Wash the cells once with 10 mL of PBS (-). Centrifuge the sample at 1,450 x *g* for 5 min at 4 °C, and discard the supernatant.Lyse the cells with ice-cold Lysis buffer A (1 mL of Lysis buffer A per 1 x 10^7^ of the cells) by gentle pipetting.Sonicate the sample in a 1.5 mL tube with following conditions; set amplification of the sonicator at 25%, and sonicate for 10 s.Centrifuge the sample at 20,400 x *g*for 15 min at 4 °C.Collect the supernatant. Transfer 1 mL each of the supernatant into 1.5 mL microcentrifuge tubes. CAUTION: Perform all procedures under RNase-free conditions.

3.  **Immunoprecipitation** Pre-clear the lysate from step 3.2.6 by adding 40 µL (bead volume 20 µL) of prewashed protein A-agarose beads per 1 mL of the lysate. Mix well by inverting the tube several times and rotate the sample for 30 min at 4 °C.Centrifuge the sample at 13,000 x *g*for 1 min at 4 °C, and recover the supernatant.Add 40 µL (bed volume 20 µL) of prewashed protein A-agarose beads and 10 µg of anti-human TERT antibody (clone: 10E9-2)[@B7] into the pre-cleared lysate. Mix well by inverting the tube several times and rotate the sample at 4 °C over night.Centrifuge the sample at 3,300 x *g* for 0.5 min at 4 °C, and remove the supernatant.Wash the beads with Wash buffer 1: add 1 mL of Wash buffer 1 to the beads, mix well by inverting the tube, and rotate the sample for 5 min at 4 °C. Centrifuge the sample at 3,300 x *g* for 0.5 min at 4 °C, and remove the supernatant. Repeat this step three additional times.Wash the beads once with AGC solution containing 2 mM CaCl~2~: add 1 mL of AGC solution containing 2 mM CaCl~2~to the beads, mix well by inverting the tube, and rotate the sample for 5 min at 4 °C. Centrifuge the sample at 3,300 x *g* for 0.5 min at 4 °C, and remove the supernatant.Treat the beads with Micrococcal nuclease (MNase): prepare the MNase reaction mixture described in **Table 1**. Resuspend the beads in 60 µL of the MNase reaction mixture by gentle pipetting. Shake the sample gently (20 to 25 rpm) on a turntable of a shaker set in a Peltier-type incubator for 15 min at 25 °C. NOTE: It is very important to use an undulating shaker and strictly follow the speed limit in this step. Other type of shakers, such as rotating mixers, are not recommended.Centrifuge the sample at 3,300 x *g* for 0.5 min at 4 °C, and remove the supernatant.Wash the beads twice with AGC solution containing 3 mM EGTA: add 1 mL of AGC solution containing 3 mM EGTA to the beads, mix well by inverting the tube, and rotate the sample for 5 min at 4 °C. Centrifuge the sample at 3,300 x *g* for 0.5 min at 4 °C, and remove the supernatant. Repeat this step once.Wash the beads once with Wash buffer 2: add 1 mL of Wash buffer 2to the beads, mix well by inverting the tube, and rotate the sample for 5 min at 4 °C. Centrifuge the sample at 3,300 x *g* for 0.5 min at 4 °C, and remove the supernatant. Keep the beads on ice while setting up RdRP reaction. CAUTION: Perform all procedures under RNase-free conditions.

4.  **RdRP reaction** Prepare a RdRP reaction mixture in a new tube as described in **Table 2**.Add 6 µL of \[α-^32^P\]UTP (3,000 Ci/mmol) to the mixture and mix well by pipetting. NOTE: \[α-^32^P\]ATP, \[α-^32^P\]CTP, or \[α-^32^P\]GTP can be used for the reaction instead of \[α-^32^P\]UTP.Add 1 µL of template RNA (1 µg/µL) to the mixture and mix well by pipetting. NOTE: To establish the RdRP assay, the following RNA template is recommended: 5\'-GGGAUCAUGUGGGUCCUAUUACAUUUUAAACCCA-3\' [@B8].Resuspend the beads with 20 µL of the RdRP reaction mixture from step 3.4.3 by pipetting.Shake the sample gently (20 to 25 rpm) on a turntable of a shaker set in a peltier-type incubator for 2 h at 32 °C.Add 5.4 µL of Proteinase K (20 mg/mL) and 45.4 µL of 2x Proteinase K buffer to the reaction mixture. Mix by pipetting and shake (20 to 25 rpm) the sample on a turntable set in a Peltier-type incubator for 30 min at 37 °C.Add 109.2 µL of RNase-free water to the sample.Add 200 µL of acid phenol-chloroform to the sample. Mix well by vortex, and then centrifuge the sample at 21,100 x *g*for 5 min at room temperature. Transfer the aqueous phase to a new tube. Repeat this step once.Add 20 µL of 3 M sodium acetate (pH = 5.2), 4 µL of precipitation carrier and 250 µL of ethanol to the aqueous phase. Shake the tube well for mixing, then centrifuge the sample at 21,100 x *g*for 20 min at 4 °C. Discard the supernatant.Wash the pellet with 300 µL of cold 70% (vol/vol) ethanol stored at -20 °C. Centrifuge the sample at 21,100 x *g*for 15 min at 4 °C.Discard the supernatant and air-dry the pellet. CAUTION: Perform all procedures under RNase-free conditions. NOTE: The pellet from step 3.4.11 can be stored at -20 °C for at least 2 days.

5.  **RNase treatment** Resuspend the pellet from step 3.4.11 in 20 µL of RNase-free water.Prepare a RNase reaction mixture in a new tube as described in **Table 3**.Add 180 µL of the RNase reaction mixture to the sample, and incubate the tube for 2 h at 37 °C.Add 2.3 µL of 10% (vol/vol) SDS to the sample and incubate for 15 min at 37 °C.Add 2 µL of Proteinase K (20 mg/mL) to the sample and incubate for 15 min at 37 °C.Add 205 µL of acid phenol-chloroform to the sample. Mix well by vortex, then centrifuge the sample at 21,100 x *g*for 5 min at room temperature. Transfer the aqueous phase to a new tube.Add 20 µL of 3 M sodium acetate (pH 5.2), 4 µL of precipitation carrier and 250 µL of ethanol to the aqueous phase. Shake the tube well for mixing, then centrifuge the sample at 21,100 x *g*for 20 min at 4 °C. Discard the supernatant.Wash the pellet with 300 µL of cold 70% (vol/vol) ethanol stored at -20 °C. Centrifuge the sample at 21,100 x *g*for 15 min at 4 °C.Discard the supernatant and air-dry the pellet. NOTE: The pellet from step 3.5.9 can be stored at -20 °C for at least 2 days.

6.  **Gel electrophoresis and autoradiography** Resuspend the sample with 20 µL of RNase-free water.Add 20 µL of 2x loading buffer.Boil the sample for 10 min at 95 °C. Crush the sample on the ice.Run the gel. In case the template size is 34 nts (see also step 3.4.3), 7 M Urea-10% polyacrylamide gel is used for denaturing gel electrophoresis.Dry the gel with a gel dryer.Expose the film to the dried-gel within an X-ray cassette with an intensifying screen at -80 °C.

Representative Results
======================

With the recommended RNA template, radioactive RdRP products are observed between 20 to 30 nucleotides (nt) specifically in HeLa cells in mitotic phase after overnight exposure ([Figure 1A](#F1){ref-type="fig"}). Typically, signal intensity of the RdRP products demonstrates two peaks that are positioned around 25 nt and 30 nt in consonance with the size distribution of the products confirmed by next generation sequencing[@B8]. In contrast to mitotic cells, HeLa cells without synchronization demonstrate almost absence of the 20--30 nt radioactive products. Oval signals, that are placed below 20 nt in all samples, are nonspecific drifts.

In case that there is only a \~30 nt product with weak signal in mitotic HeLa cells, it indicates that the RdRP reaction did not go well. For example, if MNase treatment is performed roughly and inappropriately, the signal intensity in mitotic HeLa cells decreases significantly ([Figure 1B](#F1){ref-type="fig"}). RdRP reaction performed with old HMD solution also reduces the products ([Figure 1C](#F1){ref-type="fig"}).

[Figure 1](#F1){ref-type="fig"}**: Representative RdRP products of endogenous TERT in mitotic HeLa cells**. **(A)** Three representative results of the IP-RdRP assay in HeLa cells treated with nocodazole (manipulated) or DMSO (unmanipulated). The chemically synthesized 34 nt RNA was used as a template. **(B)** IP-RdRP assay in mitotic HeLa cells performed with inappropriate MNase treatment. **(C)** IP-RdRP assay in mitotic HeLa cells performed with either fresh or old HMD solution. [Please click here to view a larger version of this figure.](https://cloudflare.jove.com/files/ftp_upload/57021/57021fig1large.jpg)

  ---------------------------------- -------------
  **Reagents**                       **Volume **
  Micrococcal Nuclease, 20 U/µL      1 µL
  Micrococcal Nuclease Buffer, 10x   8 µL
  RNase-free water                   51 µL
  ---------------------------------- -------------

**Table 1: MNase reaction mix component.**

  -------------------------- -------------
  **Reagents**               **Volume **
  CHAPS, 0.07% (wt/vol)      6 µL
  HMD solution               2 µL
  rATP, 80 mM                0.5 µL
  rGTP, 8 mM                 1 µL
  rUTP, 0.4 mM               1 µL
  rCTP, 8 mM                 1 µL
  RNase inhibitor, 40 U/µL   0.5 µL
  RNase-free water           1 µL
  -------------------------- -------------

**Table 2: RdRP reaction mix component.**

  --------------------------------- -------------
  **Reagents**                      **Volume **
  RNase ONE Ribonuclease, 10 U/µL   0.2 µL
  Reaction Buffer, 10x              20 µL
  RNase-free water                  159.8 µL
  --------------------------------- -------------

**Table 3: Ribonuclease reaction mix component.**

Discussion
==========

The IP-RdRP assay is a sensitive method to detect RdRP activity of human TERT. TERT protein is highly expressed in mitotic HeLa cells, in which TERT forms the RdRP complex[@B7][@B8][@B9]. This suggests that mitotic HeLa cells are an optimal material to detect RdRP activity. In the protocol described above, mitotic and non-synchronized HeLa cells are included as a positive and a negative example, respectively. As shown in [Figure 1A](#F1){ref-type="fig"}, RdRP assay products from the recommended RNA template in mitotic HeLa cells show broad radioactive signals between 20 to 30 nt. In addition to HeLa cells, we have performed the assay with different types of cell lines, and found that the signal pattern can be changed in different cell types[@B8]: some show a strong signal only around 30 nt, some show a similar pattern with HeLa cells. We have also performed the assay with RNA templates other than the 34 nt template[@B7], short and long (\~300 nt) RNAs with various sequences, and successfully obtained RdRP products from those templates although there may be some preference. For the first trial, however, we recommend using HeLa cells in mitotic phase and the 34 nt RNA template. RdRPs can generate double-stranded RNA both in a primer-dependent and in a primer-independent manner[@B10]. We have reported that TERT preserves this property as human RdRP[@B6][@B8]; TERT synthesizes dsRNA from an RNA template with 3\'-foldback structure through a back-priming mechanism[@B6]. For the 34 nt RNA template, TERT synthesizes complementary strands without using primers[@B8]. To specifically detect RdRP products synthesized in a primer-independent manner,*i.e. de novo*synthesized RNA products, \[α-^32^P\]NTP can be replaced with \[γ-^32^P\]NTP in the RdRP reaction[@B8].

MNase treatment of TERT immune complexes on beads is a critical step to achieve desired results. If the MNase treatment is performed too long or with intensive shaking, the RdRP products would be reduced remarkably. To avoid such a trouble, we strongly recommend to strictly follow the protocol carefully. HMD solution is another critical factor for success. If you find that the signals are very weak, replace the HMD solution to a newly prepared one.

Throughout the protocol, one should take great care to avoid RNase contamination. Ribonuclease treatment should be performed with dedicated equipment. After manipulating the Ribonuclease, one should discard tips and tubes with RNase immediately, eliminate RNase with specialized solution (*e.g.* RNase Quiet), and change groves.

TERT interacts with not only *TERC*but also many kinds of endogenous RNAs, and we have reported part of them[@B6]. Modification in the IP-RdRP assay, such as the IP-RdRP assay without MNase treatment, will provide a full list of endogenous RNA templates for TERT-associated RdRP activity and bioinformatic guide on their sequence features. We have successfully applied this protocol to tissue lysate. Because TERT is expressed in a variety of normal and tumor tissues, this assay might be useful to investigate non-canonical enzymatic function of TERT in human.
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